Gujarat Themis Acquires Sanofi Brands, MicroBiopharm Japan
Gujarat Themis Biosyn Limited will acquire 13 brands from Sanofi for ~EUR 158 million and MicroBiopharm Japan for ~JPY 21.5 billion (~₹1,300 crore). Q4 FY26 revenue grew 17% YoY to ₹44.2 crore, with PAT at ₹10.9 crore. FY26 PAT was ₹46.68 crore.
The acquisitions of Sanofi's brand portfolio and MicroBiopharm Japan are transformative for the company, representing significant strategic expansion into new markets and therapeutic areas, and a move towards becoming a global CDMO. These are material events with a high potential impact on future growth and market position.
The company announced two major strategic acquisitions, which are expected to significantly expand its global reach, product portfolio, and capabilities. Positive financial results for Q4 FY26 and FY26 also contribute to the positive sentiment.
Gujarat Themis Biosyn Limited has announced significant strategic moves to expand its global presence and capabilities.
The company has entered into an asset purchase agreement to acquire a portfolio of 13 brands from Sanofi, France, for approximately EUR 158 million. This acquisition, funded by a mix of debt and equity, includes established brands in the tuberculosis and anti-infective therapy areas, with a global reach across over 55 countries. The deal is expected to be EPS accretive and enhance the company's value chain integration.
Additionally, Gujarat Themis Biosyn Limited is set to acquire Japan-based MicroBiopharm Japan Co., Ltd. for JPY 21.5 billion (approximately ₹1,300 crore) through a wholly owned subsidiary. This acquisition is anticipated to close by Q2 FY2027, subject to regulatory approvals. It will broaden the company's product portfolio in oncology, immunosuppressants, and peptides, and enhance its R&D capabilities and global customer access, furthering its transition into a fermentation-based CDMO.
Financially, for Q4 FY26, the company reported a revenue of ₹44.2 crore, a 17% year-on-year increase. EBITDA rose by 20.7% to ₹19.4 crore, and PAT stood at ₹10.9 crore. For the full fiscal year FY26, revenue was ₹165.82 crore, while PAT was ₹46.68 crore. The company is also investing in a hybrid renewable power project to optimize costs and improve its ESG profile.
The company's Managing Director, Dr. Sachin Patel, highlighted the strong sales volumes, operational efficiencies, and strategic inorganic expansion initiatives as key drivers of growth. He also noted the commissioning of R&D and API units and the development of a new fermentation block in India.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.